Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced today that its programmed death‑1...
Others
WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion
WuXi AppTec (Shanghai) Co., Ltd., a wholly‑owned subsidiary of Wuxi AppTec Co., Ltd. (SHA: 603259,...
Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC
Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted...
Prellis Biologics and Eli Lilly Announce AI‑Driven Antibody Discovery Collaboration
Prellis Biologics, Inc. and global biopharma leader Eli Lilly & Co. (NYSE: LLY) today announced...
GE Healthcare Eyes Sale of China Unit Amid Revenue Decline
GE Healthcare Technologies Inc. (NASDAQ: GEHC) is reportedly exploring the sale of a stake in...
China’s 11th National Drug VBP Draft Unveils Major Pricing & Competition Reforms
The second‑draft rules for China’s 11th round of national centralized drug procurement (VBP 11th) have...
Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP
The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi’s (NASDAQ: SNY) Wayrilz...
HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge
China-based HitGen Inc. (SHA: 688222) on Aug 27, 2025 released its semi‑annual financial results for...
BioArctic & Novartis Announce BrainTransporter‑Enabled Neurodegeneration Collaboration – Up to $772 M Potential Pay‑Out
Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license...
Xuanzhu Biopharma’s XZP-3621 Approved for ALK-Positive NSCLC in China
Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),...
DATROWAY Approved in China for HR-Positive, HER2-Negative Breast Cancer
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) announced that DATROWAY has been approved...
Minova’s MI078 Shows Promising Results in Postpartum Depression Trial
Nanjing-based Minova Pharmaceuticals Co., Ltd. has announced positive results from a Phase 2 clinical trial...
Ascletis Pharma Reports Positive Preclinical Results for ASC47 in Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) announced encouraging efficacy results from preclinical trials of ASC47,...
Shanghai Moyang Biotechnology Secures Hundreds of Millions in Funding to Expand Global Reach
Shanghai Moyang Biotechnology Co., Ltd. announced on August 8, 2025, that it has successfully closed...
Sunshine Lake Pharma Makes History With Dual-Entity Restructuring Listing on HKEX
Guangdong China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main...
China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment
China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...
GSK’s Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced today that Blenrep has received European Union (EU) approval...
Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name:...
Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China
Japan-based Eisai (TYO: 4523) announced the official commercial release of the first batch of its...
Chia Tai Tianqing’s Anlotinib Granted NMPA Approval for Soft Tissue Sarcoma
China-based Chia Tai Tianqing Pharmaceutical announced that its anlotinib (trade name: FOCUS V) has received...